Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06345183
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Real-World Outcomes of NivolumabIpilimumab and PembrolizumabLenvatinib Among US Advanced Renal Cell Carcinoma aRCC Patients
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma aRCC Patients Receiving NivolumabIpilimumab or PembrolizumabLenvatinib in US Oncology Practice
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This observational study aims to describe demographic clinical characteristics treatment patterns outcomes of participants with advanced Renal Cell Carcinoma aRCC receiving either Nivolumab Ipilimumab or Pembrolizumab Lenvatinib combination therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None